• Something wrong with this record ?

Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

H. Studentova, K. Hola, B. Melichar, M. Spisarova

. 2024 ; 24 (6) : 339-345. [pub] 20240417

Language English Country England, Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc24013704

INTRODUCTION: Immunotherapy represents a significant and essential component of renal carcinoma therapy (RCC), but the selection of an optimal regimen for an individual patient remains unclear. Despite significant improvements in therapeutic options for RCC, predictive biomarkers for immunotherapeutic agents remain elusive. Neopterin is a biomarker of cell-mediated immune response, with concentrations increased in different disorders, including cancer. High neopterin levels herald, in general, a poor prognosis. AREAS COVERED: This review briefly overviews the contemporary clinical data on biomarkers in metastatic RCC therapy, focusing on neopterin. EXPERT OPINION: Elevated neopterin levels have been observed in tumors of different primary locations. Research indicates that neopterin may serve as a potential biomarker for assessing the inflammatory status associated with certain cancers. However, it is necessary to interpret neopterin levels in the context of a comprehensive clinical evaluation, as elevated neopterin alone is not specific to cancer and can be influenced by other factors, including comorbid conditions. Neopterin has also been identified as a prognostic biomarker. An increasing neopterin level in serum and urine is associated with advanced cancer, but the role as a potential predictor of response to immunotherapy has yet to be established. A reliable biomarker for optimal therapy selection in metastatic RCC is still putative.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013704
003      
CZ-PrNML
005      
20241210101328.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14737140.2024.2341734 $2 doi
035    __
$a (PubMed)38596831
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Studentova, Hana $u Department of Oncology, University Hospital, Olomouc, Czech Republic $u Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0000000321059258
245    10
$a Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors / $c H. Studentova, K. Hola, B. Melichar, M. Spisarova
520    9_
$a INTRODUCTION: Immunotherapy represents a significant and essential component of renal carcinoma therapy (RCC), but the selection of an optimal regimen for an individual patient remains unclear. Despite significant improvements in therapeutic options for RCC, predictive biomarkers for immunotherapeutic agents remain elusive. Neopterin is a biomarker of cell-mediated immune response, with concentrations increased in different disorders, including cancer. High neopterin levels herald, in general, a poor prognosis. AREAS COVERED: This review briefly overviews the contemporary clinical data on biomarkers in metastatic RCC therapy, focusing on neopterin. EXPERT OPINION: Elevated neopterin levels have been observed in tumors of different primary locations. Research indicates that neopterin may serve as a potential biomarker for assessing the inflammatory status associated with certain cancers. However, it is necessary to interpret neopterin levels in the context of a comprehensive clinical evaluation, as elevated neopterin alone is not specific to cancer and can be influenced by other factors, including comorbid conditions. Neopterin has also been identified as a prognostic biomarker. An increasing neopterin level in serum and urine is associated with advanced cancer, but the role as a potential predictor of response to immunotherapy has yet to be established. A reliable biomarker for optimal therapy selection in metastatic RCC is still putative.
650    12
$a neopterin $7 D019798
650    12
$a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
650    _2
$a lidé $7 D006801
650    12
$a nádory ledvin $x patologie $x farmakoterapie $7 D007680
650    _2
$a prognóza $7 D011379
650    12
$a nádorové biomarkery $x metabolismus $7 D014408
650    12
$a inhibitory kontrolních bodů $x aplikace a dávkování $x farmakologie $7 D000082082
650    12
$a imunoterapie $x metody $7 D007167
650    12
$a metastázy nádorů $7 D009362
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Holá, Kateřina $u Department of Oncology, University Hospital, Olomouc, Czech Republic $u Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0000000301725217 $7 ola20231189438
700    1_
$a Melichar, Bohuslav $u Department of Oncology, University Hospital, Olomouc, Czech Republic $u Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Spisarova, Martina $u Department of Oncology, University Hospital, Olomouc, Czech Republic $u Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
773    0_
$w MED00174405 $t Expert review of anticancer therapy $x 1744-8328 $g Roč. 24, č. 6 (2024), s. 339-345
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38596831 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20241210101324 $b ABA008
999    __
$a ok $b bmc $g 2143478 $s 1225570
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 6 $d 339-345 $e 20240417 $i 1744-8328 $m Expert review of anticancer therapy $n Expert Rev Anticancer Ther $x MED00174405
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options